Local News

Duke to start trial of promising COVID treatment

Posted August 2, 2020 1:17 p.m. EDT
Updated August 2, 2020 1:18 p.m. EDT

Coronavirus research

On Sunday, Duke announced that the Duke Human Vaccine Institute (DHVI) was given approval for a clinical trial that, if effective, could advance COVID care until a vaccine can be developed.

The approval means the DHVI can launch Phase 1 of the clinical trial for one of the most promising antibody treatments for COVID-19.

"This would be a temporary treatment until a vaccine is developed," said Duke Today in a statement.

The DHVI is also developing a pan-coronavirus vaccine to combat future iterations of COVID-19 or similar viruses, as well as if saliva could be used as an accurate indicator for COVID-19, according to Duke Today.

This video released by Duke Health Development provides a deeper look into the trials and potential for the antibody treatment.

Our commenting policy has changed. If you would like to comment, please share on social media using the icons below and comment there.